1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Global Obstetrics Partnering 2010-2015

Global Obstetrics Partnering 2010-2015

  • July 2015
  • -
  • Currentpartnering
  • -
  • 150 pages

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.

The Obstetrics Partnering 2010-2015 report provides comprehensive understanding and unprecedented access to the obstetrics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter obstetrics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors obstetrics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 500 links to online copies of actual obstetrics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of obstetrics dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in obstetrics dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading obstetrics deals since 2010. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of obstetrics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all obstetrics deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all obstetrics partnering deals signed and announced since 2010. The chapter is organized by specific obstetrics therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all obstetrics partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in obstetrics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of obstetrics technologies and products.
Obstetrics Partnering 2010-2015 provides the reader with the following key benefits:

In-depth understanding of obstetrics deal trends since 2010
Access obstetrics deal headline, upfront, milestone and royalty data
Research hundreds of actual contracts between obstetrics partner companies
Comprehensive access to over 500 links to actual obstetrics deals entered into by the world’s biopharma companies
Indepth review of obstetrics deals entered into by the leading fifty bigpharma companies
Benchmark the key deal terms companies have agreed in previous deals
Identify key terms under which companies partner obstetrics opportunities
Uncover companies actively partnering obstetrics opportunities

Report scope

Obstetrics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to pediatrics trends and structure of deals entered into by leading companies worldwide.

Obstetrics Partnering Terms and Agreements includes:

Trends in obstetrics dealmaking in the biopharma industry since 2010
Analysis of obstetrics deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of obstetrics deal contract documents
Comprehensive access to over 500 obstetrics deal records
The leading obstetrics deals by value since 2010
Most active obstetrics dealmakers since 2010

In Obstetrics Partnering Terms and Agreements, available deals and contracts are listed by:

Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Table Of Contents

Global Obstetrics Partnering 2010-2015
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in obstetrics dealmaking
2.1. Introduction
2.2. Obstetrics partnering over the years
2.3. Bigpharma obstetrics dealmaking activity
2.4. Bigpharma not active in pediatrics
2.5. Obstetrics partnering by deal type
2.6. Obstetrics partnering by industry sector
2.7. Obstetrics partnering by stage of development
2.8. Obstetrics partnering by technology type
2.9. Obstetrics partnering by obstetrics indication
2.10. Average deal terms for obstetrics
2.10.1 Obstetrics headline values
2.10.2 Obstetrics upfront payments
2.10.3 Obstetrics milestone payments
2.10.4 Obstetrics royalty rates

Chapter 3 - Leading obstetrics deals
3.1. Introduction
3.2. Top obstetrics deals by value
3.3. Top obstetrics deals involving bigpharma

Chapter 4 - Bigpharma obstetrics deals
4.1. Introduction
4.2. How to use bigpharma partnering deals
4.3. Bigpharma obstetrics partnering company profiles
Abbott
Allergan
AstraZeneca
Baxter International
Biogen Idec
Bristol-Myers Squibb
Daiichi Sankyo
Eisai
Forest Laboratories
GlaxoSmithKline
Johnson and Johnson
Merck and Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Pfizer
Roche
Sanofi
Shionogi
Teva

Chapter 5 - Obstetrics partnering contracts directory
5.1. Introduction
5.2. By deal type
Collaborative RandD
Contract service
Co-promotion
Development
Distribution
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Supply
5.3. By stage of development
Discovery
Preclinical
Phase I
Phase III
Marketed
5.4. By technology type
Assays
Biological compounds
Discovery tools
Drug delivery
Genomics
Natural product
Orphan drug
Peptides
Screening
Small molecules

Chapter 6 - Obstetrics dealmaking by indication
6.1. Introduction

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 - Directory of obstetrics deals by company A-Z 2010-2012
Appendix 2 - Directory of obstetrics deals by deal type 2010-2012
Appendix 3 - Directory of obstetrics deals by stage of development 2010-2012
Appendix 4 - Directory of obstetrics deals by technology type 2010-2012
Appendix 5 - Deal type definitions

About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form - Reports
Order Form - Therapy Reports

Table of figures
Figure 1: Obstetrics partnering since 2010
Figure 2: Bigpharma - top 50 - obstetrics deals 2010 to 2012
Figure 3: Bigpharma obstetrics deal frequency - 2010 to 2012
Figure 4: Inactive bigpharma in obstetrics 2010-2012
Figure 5: Obstetrics partnering by deal type since 2010
Figure 6: Obstetrics partnering by industry sector since 2010
Figure 7: Obstetrics partnering by stage of development since 2010
Figure 8: Obstetrics partnering by technology type since 2010
Figure 9: Obstetrics partnering by target since 2010
Figure 10: Obstetrics deals with a headline value
Figure 11: Obstetrics deal headline value distribution, US$million - discovery stage
Figure 12: Obstetrics deal headline value distribution, US$million - preclinical stage
Figure 13: Obstetrics deal headline value distribution, US$million - phase I stage
Figure 14: Obstetrics deal headline value distribution, US$million - phase II stage
Figure 15: Obstetrics deal headline value distribution, US$million - phase III stage
Figure 16: Obstetrics deal headline value distribution, US$million - regulatory stage
Figure 17: Pediatrics deal headline value distribution, US$million - marketed stage
Figure 18: Summary median headline value by stage of development, 2010-2012
Figure 19 Obstetrics deals with upfront payment values
Figure 20: Obstetrics deal upfront payment distribution, US$million - discovery stage
Figure 21: Obstetrics deal upfront payment distribution, US$million - preclinical stage
Figure 22: Obstetrics deal upfront payment distribution, US$million - phase I stage
Figure 23: Obstetrics deal upfront payment distribution, US$million - phase II stage
Figure 24: Obstetrics deal upfront payment distribution, US$million - phase III stage
Figure 25: Obstetrics deal upfront payment distribution, US$million - regulatory stage
Figure 26: Obstetrics deal upfront payment distribution, US$million - marketed stage
Figure 27: Summary median upfront payments by stage of development, 2010-2012
Figure 28: Obstetrics deals with milestone payments
Figure 29: Obstetrics deal milestone distribution, US$million - discovery stage
Figure 30: Obstetrics deal milestone distribution, US$million - preclinical stage
Figure 31: Obstetrics deal milestone distribution, US$million - phase I stage
Figure 32: Obstetrics deal milestone distribution, US$million - phase II stage
Figure 33: Obstetrics deal milestone distribution, US$million - phase III stage
Figure 34: Obstetrics deal milestone distribution, US$million - regulatory stage
Figure 35: Obstetrics deal milestone distribution, US$million - marketed stage
Figure 36: Obstetrics health deals with royalty rates, %
Figure 37: Obstetrics deal royalty rate distribution, US$million - discovery stage
Figure 38: Obstetrics deal royalty rate distribution, US$million - preclinical stage
Figure 39: Obstetrics deal royalty rate distribution, US$million - phase I stage
Figure 40: Obstetrics deal royalty rate distribution, US$million - phase II stage
Figure 41: Obstetrics deal royalty rate distribution, US$million - phase III stage
Figure 42: Obstetrics deal royalty rate distribution, US$million - regulatory stage
Figure 44: Summary median royalty rate by stage of development, 2010-2012
Figure 45: Top obstetrics deals by value since 2010
Figure 46: Top obstetrics deals signed by bigpharma value since 2010
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global and Chinese Obstetrics and Gynecology Scissors Industry, 2016 Market Research Report

Global and Chinese Obstetrics and Gynecology Scissors Industry, 2016 Market Research Report

  • $ 3000
  • Industry report
  • November 2016
  • by Prof Research

The ’Global and Chinese Obstetrics and Gynecology Scissors Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global Obstetrics and Gynecology ...

Global Obstetrics Partnering 2010-2016: Deal trends, players and financials

Global Obstetrics Partnering 2010-2016: Deal trends, players and financials

  • $ 2995
  • Industry report
  • November 2016
  • by Currentpartnering

Global Obstetrics Partnering 2010 to 2016 provides the full collection of Obstetrics disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010. Trends in Obstetrics ...

Global and Chinese Clamp used in Obstetrics and Gynecology Industry, 2016 Market Research Report

Global and Chinese Clamp used in Obstetrics and Gynecology Industry, 2016 Market Research Report

  • $ 2800
  • Industry report
  • November 2016
  • by Prof Research

The 'Global and Chinese Clamp used in Obstetrics and Gynecology Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Clamp used in Obstetrics ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.